Why Healthcare AI Companies Are Choosing Static Models Over Smart Ones: The Regulatory Paradox Reshaping Medical Innovation
The FDA's preference for locked algorithms over adaptive learning systems is forcing developers to abandon the very features that make AI powerful, creating a strategic dilemma between innovation and market access.
New Transparency Rules Could Make or Break Your AI Diagnostic Tool's Market Access
STARD-AI guidelines published in Nature Medicine establish mandatory disclosure standards that regulators and journals now require for AI diagnostic accuracy studies.
Healthcare Diagnostics Giant Abbott Faces Dual Cyberattacks as Notorious Hacking Group Claims Responsibility
Abbott Laboratories is investigating two separate security incidents affecting its cancer diagnostics systems and laboratory portal, with cybercriminal group ShinyHunters claiming the breach.
The Accountability Black Hole in Healthcare AI: Why Your Audit Logs Can't Trace Agent Actions to Real Clinicians
A new open-source system tackles the compliance crisis facing hospitals deploying AI agents that act on patient data without recording which human authorized the action.
Congress Targets 40-Year Treatment Gap with $500M AI Investment for Childhood Cancer
New bipartisan legislation aims to end decades of stagnant pediatric oncology protocols by mandating data interoperability standards and funding AI-driven precision medicine research.
The Regulatory Blind Spot Putting European Patients at Risk: Why Primary Care AI Is Escaping Medical Device Oversight
General-purpose AI tools are being deployed for clinical decision-making across European primary care without required regulatory clearance, creating an accountability vacuum that threatens patient safety and undermines compliant medical device manufacturers.
FDA Reviews Infant Eczema Treatment That Could Transform Pediatric Dermatology AI Systems
Arcutis Biotherapeutics' ZORYVE cream enters FDA review for infant atopic dermatitis, prompting updates to clinical decision support algorithms and treatment recommendation platforms.
Nine Years to Diagnosis: How New Primary Care Tests Could End the Endometriosis Waiting Game
NICE approves first non-invasive endometriosis tests for GP surgeries, potentially eliminating the need for invasive surgery and dramatically shortening the diagnostic journey for millions of women.
Digital Accountability Platform Tackles Nigeria's Mental Health Crisis Through Real-Time Policy Monitoring
New transparency tracker exposes implementation gaps in a nation where 60 million citizens face mental health challenges but only 300 psychiatrists are available to treat them.
India Rewrites the Rulebook for Stem Cell Therapies and Essential Drug Pricing in Landmark Healthcare Reform
New regulatory framework brings gene and cell therapies under formal oversight while controversial pricing changes could reshape access to essential medicines
India Launches Unified Drug Database to Power Next-Generation Healthcare AI
New national registry standardizes pharmaceutical data across the world's most populous nation, creating infrastructure for AI-driven clinical tools and medication safety systems.
The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design
FDA's new guidance on Bayesian statistical methods opens the door to adaptive clinical trials that could accelerate drug development while reducing costs and patient exposure to ineffective treatments.
Why Drug Trials Are About to Get Smarter: FDA Embraces Statistical Revolution That Could Save Years of Research
FDA's new guidance on Bayesian statistical methods opens the door to adaptive clinical trials that could accelerate drug development while reducing costs and patient exposure to ineffective treatments.
FDA Approves Australian Blowfly Larvae to Devour Dead Tissue in Chronic Wounds
FDA clears first medical maggot product using Australian sheep blowfly larvae, breaking the single-species monopoly in biological wound debridement therapy.
FDA Launches Elsa 4.0 and HALO Platform to Modernize Internal AI Capabilities
The FDA has launched Elsa 4.0 and the HALO (Health AI and Learning Operations) platform, consolidating the agency's internal AI and data infrastructure to accelerate regulatory reviews and modernize how the agency processes scientific evidence.